Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Telmisartan has been used as an AT1 receptor antagonist to study its effects on mouse models of myocardial infarction. This study reported that telmisartan inhibited the CCN1 upregulation and reduced CCN2 levels atrial cardiomyocytes. Telmisartan has also been used to evaluate its effect on the expression of CCN1 in kidney cortex of mice subjected to myocardial infarction. Furthermore, telmisartan has been used to test its efficacy against tumor growth in mouse models of colorectal cancer.

Biochem/physiol Actions

Telmisartan is a non-peptide AT₁ angiotensin receptor antagonist.

Features and Benefits

This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

10, 50 mg in glass bottle

Preparation Note

Telmisartan is soluble in DMSO at a concentration that is greater than 5 mg/ml. It is insoluble in water.